{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "regularMarketChangePercent": -0.657891, "regularMarketPrice": 30.2, "currency": "EUR", "exchange": "FRA", "shortName": "CELLDEX THER.  DL-,001", "longName": "Celldex Therapeutics, Inc.", "messageBoardId": "finmb_9620565", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "marketState": "REGULAR", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1198825200000, "priceHint": 2, "regularMarketChange": -0.19999886, "regularMarketTime": 1683871252, "regularMarketDayHigh": 30.2, "regularMarketDayRange": "30.2 - 30.2", "regularMarketDayLow": 30.2, "regularMarketVolume": 50, "regularMarketPreviousClose": 30.4, "bid": 30.2, "ask": 30.4, "bidSize": 0, "askSize": 0, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 30.2, "averageDailyVolume3Month": 22, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 10.640001, "fiftyTwoWeekLowChangePercent": 0.54396737, "fiftyTwoWeekRange": "19.56 - 43.44", "fiftyTwoWeekHighChange": -13.239998, "fiftyTwoWeekHighChangePercent": -0.30478817, "fiftyTwoWeekLow": 19.56, "fiftyTwoWeekHigh": 43.44, "earningsTimestamp": 1683230467, "earningsTimestampStart": 1691438400, "earningsTimestampEnd": 1691784000, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -2.32, "epsForward": -1.73, "epsCurrentYear": -1.5, "priceEpsCurrentYear": -20.133333, "sharesOutstanding": 47252500, "bookValue": 6.408, "fiftyDayAverage": 34.4228, "fiftyDayAverageChange": -4.2227974, "fiftyDayAverageChangePercent": -0.122674435, "twoHundredDayAverage": 34.8953, "twoHundredDayAverageChange": -4.695301, "twoHundredDayAverageChangePercent": -0.13455395, "marketCap": 1436233472, "forwardPE": -17.456648, "priceToBook": 4.712859, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.5 - Strong Buy", "symbol": "TCE2.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Perryville III Building", "address2": "Suite 220 53 Frontage Road", "city": "Hampton", "state": "NJ", "zip": "08827", "country": "United States", "phone": "908 200 7500", "fax": "908 454 1911", "website": "https://www.celldex.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. It has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.", "fullTimeEmployees": 148, "companyOfficers": [{"maxAge": 1, "name": "Mr. Anthony S. Marucci M.B.A.", "age": 60, "title": "Founder, Pres, CEO & Director", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": {"raw": 1139033, "fmt": "1.14M", "longFmt": "1,139,033"}, "exercisedValue": {"raw": 3905158, "fmt": "3.91M", "longFmt": "3,905,158"}, "unexercisedValue": {"raw": 8406907, "fmt": "8.41M", "longFmt": "8,406,907"}}, {"maxAge": 1, "name": "Dr. Tibor  Keler", "age": 63, "title": "Founder, Chief Scientific Officer & Exec. VP", "yearBorn": 1959, "fiscalYear": 2022, "totalPay": {"raw": 739027, "fmt": "739.03k", "longFmt": "739,027"}, "exercisedValue": {"raw": 575740, "fmt": "575.74k", "longFmt": "575,740"}, "unexercisedValue": {"raw": 5392443, "fmt": "5.39M", "longFmt": "5,392,443"}}, {"maxAge": 1, "name": "Mr. Sam  Martin", "age": 51, "title": "Sr. VP, CFO, Sec. & Treasurer", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": {"raw": 617256, "fmt": "617.26k", "longFmt": "617,256"}, "exercisedValue": {"raw": 634899, "fmt": "634.9k", "longFmt": "634,899"}, "unexercisedValue": {"raw": 3165449, "fmt": "3.17M", "longFmt": "3,165,449"}}, {"maxAge": 1, "name": "Dr. Margo  Heath-Chiozzi M.D.", "age": 65, "title": "Sr. VP of Regulatory Affairs", "yearBorn": 1957, "fiscalYear": 2022, "totalPay": {"raw": 614125, "fmt": "614.12k", "longFmt": "614,125"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 4001729, "fmt": "4M", "longFmt": "4,001,729"}}, {"maxAge": 1, "name": "Dr. Diane C. Young M.D.", "age": 65, "title": "Sr. VP & Chief Medical Officer", "yearBorn": 1957, "fiscalYear": 2022, "totalPay": {"raw": 643497, "fmt": "643.5k", "longFmt": "643,497"}, "exercisedValue": {"raw": 2042396, "fmt": "2.04M", "longFmt": "2,042,396"}, "unexercisedValue": {"raw": 1336031, "fmt": "1.34M", "longFmt": "1,336,031"}}, {"maxAge": 1, "name": "Prof. Joseph P. Schlessinger Ph.D.", "age": 77, "title": "Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1945, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Sarah  Cavanaugh", "age": 47, "title": "Sr. VP of Corp. Affairs & Admin.", "yearBorn": 1975, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Patrick  Till", "title": "Sr. Director of Investor Relations & Corp. Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Freddy A. Jimenez Esq.", "age": 53, "title": "Sr. VP & Gen. Counsel", "yearBorn": 1969, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Ronald A. Pepin", "age": 66, "title": "Chief Bus. Officer & Sr. VP", "yearBorn": 1956, "fiscalYear": 2011, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 1, "boardRisk": 2, "compensationRisk": 7, "shareHolderRightsRisk": 1, "overallRisk": 1, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}